How often cannabis-related vomiting sends adults to emergency rooms in Maine-et-Loire
Official title: Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.
Run by University Hospital, Angers · NCT06660901 · Data updated 2026-11-12
This study will see how common cannabinoid hyperemesis is in adults 18–65 who come to participating emergency departments with abdominal pain or vomiting.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University Hospital, Angers Government |
| Locations | 3 sites (Angers and 2 other locations) |
| Status | Recruiting |
| Started | July 25, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | August 28, 2025 |
| Trial ID | NCT06660901 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 who present to the participating emergency departments with abdominal pain and/or vomiting and can give informed consent are the intended participants.
✕Probably not a fit
People outside the 18–65 range, pregnant patients, those unable to complete the questionnaire, or patients whose symptoms have a clear alternative diagnosis are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational project enrolling adults aged 18–65 who present to three emergency departments in Maine‑et‑Loire with abdominal pain and/or vomiting during the study period. Patients who can consent complete a questionnaire and are screened for features of cannabinoid hyperemesis, including symptom relief with hot showers, and investigators record cannabis use history and clinical findings. The research team will calculate the prevalence of cannabinoid hyperemesis among eligible ED presentations and describe diagnostic pathways and repeat visit patterns. The study excludes pregnant people and those unable to answer the questionnaire.
Why it matters
Potential benefit: If successful, the study could help emergency clinicians recognize cannabinoid hyperemesis sooner and reduce repeat visits by guiding faster diagnosis and management.
How similar studies have gone: A prior two‑center French emergency department study estimated a 1.6% prevalence among undifferentiated acute abdominal pain cases, so similar observational approaches have produced preliminary prevalence data but broader confirmation is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 to 65 years, * Consulted the Maine et Loire adult emergency department for abdominal pain and/or vomiting for the 1st time during the study period. Exclusion Criteria: * Refusal to participate in the study * Patient unable to answer questionnaire (allophone, under guardianship, under protection, incapable of age, under legal proceedings) * Pregnant women
Where it's running
-
Angers Centre Hospitalier Universitaire (CHU)
Angers, France Recruiting -
Centre Hospitalier de Cholet
Cholet, France Recruiting -
Centre Hospitalier de Saumur
Saumur, France Recruiting
Study contacts
- Principal investigator: Julien DENIS, Doctor — Saumur Hospital Center
- Study coordinator: Julien DENIS, Doctor
- Email: julien.denis@ch-saumur.fr
- Phone: +33 2 41 53 30 30
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.